🇰🇷 Imlygic in South Korea

Imlygic (TALIMOGENE LAHERPAREPVEC) regulatory status in South Korea.

Marketing authorisation

MFDS

  • Status: likely_approved

Imlygic in other countries

Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.

Other Oncology approved in South Korea

Frequently asked questions

Is Imlygic approved in South Korea?

Yes. MFDS has authorised it.

Who is the marketing authorisation holder for Imlygic in South Korea?

Amgen is the originator. The local marketing authorisation holder may differ — check the official source linked above.